Hypertension, genotype and oral contraceptives
Related Experiment Videos
Paolo Mulatero1, Stefania Morra di Cella, Franco Veglio
1Department of Medicine and Experimental Oncology, Hypertension Unit, San Vito Hospital, University of Torino, S. San Vito 34 10133 Torino, Italy. paolo.mulatero@libero.it
Abstract:
Oral contraceptive-induced hypertension (OCIH) is a well-recognized phenomenon characterized by an increase in blood pressure levels after beginning estroprogestin therapy and a reduction to normal levels within 1 year after suspension of the therapy. The pathophysiology of this condition is still not understood: several lines of evidence indicate a role for a genetic susceptibility to the development of this disease. In this article, the epidemiology and the pathogenesis of OCIH are reviewed with particular emphasis on the genetic influence in light of the most recent studies in this field.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Factors affecting Blood pressure
Physiological Factors:
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase